Table 2.
Cox univariate analysis of EFS, OS, and LC at 5 and 7 years for intracranial tumors (n = 145)
| Variable | N | Events | Deaths | LF | Event-Free Survival (%) | Overall Survival (%) | Local Control (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years | HR (95% CI) | P | Years | HR (95% CI) | P | Years | HR (95% CI) | P | ||||||||
| 5 | 7 | 5 | 7 | 5 | 7 | |||||||||||
| Entire Cohort | ||||||||||||||||
| 145 | 52 | 22 | 32 | 68.2 | 63.4 | - | - | 86.5 | 82.6 | - | - | 79.9 | 76.1 | - | - | |
| Tumor Grade | ||||||||||||||||
| Grade II | 57 | 20 | 11 | 10 | 71.2 | 71.2 | 1.0 | 85.5 | 85.5 | 1.0 | 84.6 | 84.6 | 1.0 | |||
| Grade III | 88 | 32 | 11 | 22 | 66.5 | 56.1 | 1.5 (0.8–2.6) | 0.2 | 88.0 | 79.7 | 1.1 (0.5–2.6) | 0.8 | 76.6 | 68.3 | 2.0 (0.9–4.1) | 0.06 |
| Tumor Location | ||||||||||||||||
| Supratentorial | 43 | 11 | 2 | 11 | 77.1 | 771.1 | 1.0 | 97.4 | 92.2 | 1.0 | 74.3 | 74.3 | 1.0 | |||
| Infratentorial | 102 | 41 | 20 | 21 | 64.7 | 58.0 | 1.7 (0.9–3.3) | 0.1 | 82.8 | 79.3 | 4.0 (0.9–17.2) | 0.04 | 82.1 | 76.9 | 0.7 (0.3–1.5) | 0.4 |
| Sex | ||||||||||||||||
| Female | 77 | 25 | 11 | 17 | 71.7 | 64.8 | 1.0 | 88.6 | 86.2 | 1.0 | 80.0 | 73.1 | 1.0 | |||
| Male | 68 | 27 | 11 | 15 | 64.8 | 62.4 | 1.2 (0.7–2.0) | 0.6 | 84.4 | 78.2 | 1.3 (0.6–3.1) | 0.5 | 79.8 | 79.8 | 0.9 (0.4–1.8) | 0.8 |
| Age at Diagnosis (years) | ||||||||||||||||
| ≥3 | 79 | 25 | 10 | 15 | 68.7 | 66.7 | 1.0 | 88.9 | 83.5 | 1.0 | 80.0 | 80.0 | 1.0 | |||
| <3 | 66 | 27 | 12 | 17 | 67.6 | 60.0 | 1.2 (0.7–2.1) | 0.4 | 84.1 | 81.6 | 1.4 (0.6–3.2) | 0.4 | 79.7 | 72.1 | 1.3 (0.7–2.6) | 0.5 |
| Total Dose (Gy RBE) | ||||||||||||||||
| ≤54 | 73 | 22 | 7 | 10 | 74.8 | 65.0 | 1.0 | 91.9 | 91.9 | 1.0 | 89.0 | 81.3 | 1.0 | |||
| >54 | 72 | 30 | 15 | 22 | 61.3 | 61.8 | 1.5 (0.9–2.6) | 0.1 | 80.9 | 73.2 | 2.3 (1.0–5.7) | 0.06 | 70.4 | 70.4 | 2.5 (1.2–5.2) | 0.01 |
| Surgical Extent* | ||||||||||||||||
| GTR and NTR | 116 | 33 | 12 | 19 | 74.8 | 70.3 | 1.0 | 94.0 | 90.9 | 1.0 | 84.7 | 81.5 | 1.0 | |||
| STR | 29 | 19 | 10 | 13 | 42.3 | 35.2 | 3.5 (2.0–6.2) | <0.0001 | 56.0 | 49.0 | 4.9 (2.1–11.5) | <0.0001 | 61.0 | 53.9 | 3.4 (1.7–6.7) | 0.0006 |
| Pre-RT Chemo | ||||||||||||||||
| No | 106 | 32 | 15 | 15 | 69.8 | 66.3 | 1.0 | 89.3 | 83.7 | 1.0 | 85.3 | 83.3 | 1.0 | |||
| Yes | 39 | 20 | 7 | 17 | 64.2 | 56.8 | 1.6 (0.9–2.7) | 0.1 | 79.5 | 79.5 | 1.2 (0.5–3.1) | 0.6 | 66.7 | 59.2 | 3.1 (1.6–6.1) | 0.001 |
| Surgery to RT Interval | ||||||||||||||||
| ≤9 Weeks | 81 | 27 | 13 | 12 | 68.0 | 63.7 | 1.0 | 87.9 | 83.3 | 1.0 | 85.3 | 82.9 | 1.0 | |||
| >9 Weeks | 64 | 25 | 9 | 20 | 68.4 | 62.8 | 1.2 (0.7–2.0) | 0.6 | 84.8 | 81.6 | 0.9 (0.4–2.1) | 0.8 | 73.2 | 67.7 | 2.2 (1.1–4.6) | 0.02 |
HR, hazard ratio; RT, radiation therapy; GTR, gross total resection; NTR, near total resection; STR, subtotal resection; LC, local control
*Patients who received chemotherapy prior to radiotherapy and had no radiographic evidence of residual disease at the time of radiotherapy were analyzed with the GTR cohort.